Infographic
NotebookLM Studio overview of the clinical pathway and STEP UP message.
Podcast — Audio Overview
Deep Dive style Audio Overview from NotebookLM (~25 minutes).
Video Overview
NotebookLM Explainer video (~9 minutes).
Key takeaways for GP care
- A flat weight plateau after ~6–9 months on semaglutide 2.4 mg is expected; continuing therapy maintains loss without rebound while on drug.
- Frame treatment around health gain (pre-diabetes, knee OA, OSA/MASLD), not endless scale chasing — Monica’s ~10% is meaningful, but more may help her knees and glycaemia.
- Switching to tirzepatide 10/15 mg can add clinically meaningful further loss (head-to-head ~20% vs ~14%).
- STEP UP: semaglutide 7.2 mg (~20.7% mean) with similar permanent GI discontinuation to 2.4 mg; warn about transient dysaesthesia after the step-up.
- MRI body composition: ~85% fat / ~15% lean; sit-to-stand function improved — not a frailty signal in the trial data shown.